首页 | 本学科首页   官方微博 | 高级检索  
     


Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II,single-arm,basket trial
Affiliation:1. Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center-Herbert Irving Comprehensive Cancer Center, New York, USA;2. Department of Medicine, Medical Oncology, University of Colorado Cancer Center, Aurora, USA;3. Department of Medicine, Weill Cornell Medical College, New York, USA;4. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA;5. Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA;6. Department of Medical Oncology, Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, USA;7. Department of Hematology/Oncology, Orlando Health UF Health Cancer Center, Orlando, USA;8. Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA;9. Clinical Development, Immunomedics, Inc., Morris Plains, USA
Abstract:
Keywords:antibody–drug conjugate  SN-38  Trop-2  IMMU-132-01  TROPiCS-02
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号